Bone Resorption, Osteoclastogenesis and Adalimumab

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Broca II is the prolongation of the original study name BROCA. In BROCA study, only 25 patients participated and it was not enough to concluded clearly our hypothesis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Université de Sherbrooke
• Collaborator: AbbVie
• Treatments: Adalimumab

Criteria

Inclusion Criteria:

• Patients aged of 18 and over,

• Satisfying the 1987 American College of Rheumatology (ACR) criteria for RA

• Receiving a prescription of Adalimumab 40 mg subcutaneous every two weeks.

Exclusion Criteria:

• Patients not capable or willing to provide informed consent

• Patients starting Adalimumab less than five half-lives after the interruption of a previous anti-TNF therapy.